Xspray's Dasynoc knocked back by FDA over production once again
Xspray's Dasynoc knocked back by FDA over production once again
Xspray Pharma
Services: Amorphous protein kinase inhibitor formulations for cancer treatment using HyNap technology, improved versions of marketed drugs. | Leadership: Blake Leitch (CEO), Per Andersson (CSO) | Keywords: PKIs, cancer drugs, amorphous formulations, drug development, Stockholm